Mode
Text Size
Log in / Sign up
Phase 2 N=53 Randomized Quadruple-blind Treatment

The Antihypertensives and Vascular, Endothelial and Cognitive Function Trial

Cognitive Impairment · Hypertension · Aging

Enrolled (actual)
53
Serious AEs
0.0%
Results posted
Feb 2013
Primary outcome: Primary: Cognitive Assessment: Trail Making Test Part B — -14; 17; 4 seconds — p=0.008

Study Design & Population

Study type
Interventional
Phase
Phase 2
Interventions
candesartan (Drug); lisinopril (Drug); hydrochlorothiazide (Drug); nifedipine, long acting (Drug); metoprolol, long-acting (Drug)
Age
Adult, Older Adult · 60+ yrs
Sex
All
Sponsor
University of Southern California
Primary completion
Dec 2011

Outcome Measures

OutcomeResultp-value
PRIMARY
Cognitive Assessment: Trail Making Test Part B
-14; 17; 4 0.008 sig
PRIMARY
Cognitive Assessment: Hopkins Verbal Learning- Immediate Recall
-1; -2; -3 0.87
PRIMARY
Cognitive Assessment: Forward Digit Span Test
-0.3; 0.02; -0.04 0.79
SECONDARY
Blood Pressure Outcome: Systolic BP
28; 27; 21 0.74
SECONDARY
Blood Flow Velocity, Sitting
-0.3; -2.85; 0.35 0.81

Summary

The purpose of this study is to examine the effects of blood pressure medications on cognition and blood flow in hypertensive elderly patients with cognitive impairment. The hypothesis is that treatment with an angiotensin receptor blocker (ARB) or an angiotensin-converting enzyme inhibitor (ACEI) will be associated with a slower rate of further cognitive decline, improved cerebral blood flow and its regulation, and preserved physical function as compared to treatment with a diuretic (HCTZ), independent of blood pressure level.

Eligibility Criteria

Inclusion Criteria

  • 60 years or older
  • Hypertension
  • Cognitive criteria: score either 10 or less out of 15 for the executive clock draw test 1 (CLOX1) or less than or equal to 1 standard deviation from the corresponding age specific mean on the immediate memory subtest

Exclusion Criteria

  • Intolerance to ACEI or ARB
  • History of congestive heart failure
  • History of diabetes mellitus
  • History of stroke (less than 6 months)
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00605072). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search